Brought to you by 
GSK,Vitae develop hypertension therapies; ends
10 Nov 2008
Executive Summary
Vitae Pharmaceuticals (formerly Concurrent; focuses on therapeutics for cancer, CV, dermatology, and metabolic diseases) has licensed GlaxoSmithKline PLC exclusive worldwide rights to a series of preclinical renin inhibitors to develop as oral drugs for hypertension and related CV disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK,Vitae develop hypertension therapies; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice